A phase II trial of nilotinib in the treatment of c-KIT mutated advanced acral and mucosal melanoma (NICAM).

Trial Profile

A phase II trial of nilotinib in the treatment of c-KIT mutated advanced acral and mucosal melanoma (NICAM).

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms NICAM
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Aug 2014 Accrual to date is 912% according to United Kingdom Clinical Research Network record.
    • 21 Aug 2014 Status changed from recruiting to completed according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top